loading
Zenas Biopharma Inc stock is traded at $16.32, with a volume of 222.56K. It is up +4.48% in the last 24 hours and up +62.87% over the past month. Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$15.62
Open:
$15.69
24h Volume:
222.56K
Relative Volume:
1.29
Market Cap:
$682.73M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+23.82%
1M Performance:
+62.87%
6M Performance:
+111.13%
1Y Performance:
+0.00%
1-Day Range:
Value
$15.44
$16.67
1-Week Range:
Value
$13.07
$16.67
52-Week Range:
Value
$5.83
$26.25

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Name
Name
Zenas Biopharma Inc
Name
Phone
857-271-2954
Name
Address
852 WINTER STREET, SUITE 250, WALTHAM
Name
Employee
130
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ZBIO's Discussions on Twitter

Compare ZBIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZBIO
Zenas Biopharma Inc
16.32 598.65M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-20-25 Initiated Wedbush Outperform
Feb-04-25 Initiated Wolfe Research Outperform
Dec-16-24 Initiated H.C. Wainwright Buy
Nov-05-24 Initiated Rodman & Renshaw Buy
Oct-08-24 Initiated Citigroup Buy
Oct-08-24 Initiated Guggenheim Buy
Oct-08-24 Initiated Jefferies Buy
Oct-08-24 Initiated Morgan Stanley Overweight
View All

Zenas Biopharma Inc Stock (ZBIO) Latest News

pulisher
Jul 23, 2025

What analysts say about Zenas BioPharma Inc. stockRecord-setting profit potential - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Zenas BioPharma Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Zenas BioPharma Inc. a good long term investmentFree Consultation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Zenas BioPharma Inc. stock priceStrong return on assets - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

IgG4-Related Disease Market Outlook Driven by Advancing - openPR.com

Jul 22, 2025
pulisher
Jul 18, 2025

What makes Zenas BioPharma Inc. stock price move sharplyFree Stock Market Group - beatles.ru

Jul 18, 2025
pulisher
Jul 15, 2025

Why Zenas BioPharma Inc. stock attracts strong analyst attentionHigh Return Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Zenas BioPharma Inc. stock performs during market volatilityFree Stock Tips Group - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Zenas BioPharma Insiders Added US$2.11m Of Stock To Their Holdings - 富途牛牛

Jul 11, 2025
pulisher
Jul 11, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 10, 2025

Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

ZBIO Crosses Above Key Moving Average Level - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments - TipRanks

Jul 10, 2025
pulisher
Jul 03, 2025

Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating - Investing.com Canada

Jul 03, 2025
pulisher
Jul 03, 2025

Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma - TipRanks

Jul 03, 2025
pulisher
Jun 30, 2025

Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 2000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 27, 2025

Rhumbline Advisers Sells 27,428 Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) - Defense World

Jun 27, 2025
pulisher
Jun 20, 2025

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 20, 2025
pulisher
Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesZBIO - Finansavisen

Jun 17, 2025
pulisher
Jun 16, 2025

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO)Levi & Korsinsky Reminds Investors of June 16, 2025 - ACCESS Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

ZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

FINAL ALERT NOTICEZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsZBIO - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO - PR Newswire

Jun 16, 2025
pulisher
Jun 15, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - The Malaysian Reserve

Jun 15, 2025
pulisher
Jun 14, 2025

Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO)Contact Levi & Korsinsky Before June 16, 2025 - ACCESS Newswire

Jun 14, 2025
pulisher
Jun 14, 2025

Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class ActionContact Levi & Korsinsky - ACCESS Newswire

Jun 14, 2025
pulisher
Jun 14, 2025

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider

Jun 14, 2025
pulisher
Jun 13, 2025

Zenas BioPharma, Inc. Sued for Securities Law Violations – - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & ... - Bluefield Daily Telegraph

Jun 13, 2025
pulisher
Jun 13, 2025

ZBIO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider

Jun 13, 2025

Zenas Biopharma Inc Stock (ZBIO) Financials Data

There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):